PRKACA and colorectal carcinoma: This study demonstrated that PRKACA expression in GC and CRC displays enrichment of genes that are associated with multiple conventional chemotherapeutic agents, FDA-approved tyrosine kinase inhibitors, and β-adrenergic blockers.